SeaStar Medical Holding Business Update
SeaStar Medical announced that the FDA's Center for Biologics Evaluation and Research (CBER) determined the QUELIMMUNE Pediatric SAVE Surveillance Registry has fulfilled its post-approval study requirements. This decision allows hospitals to use the QUELIMMUNE therapy for pediatric sepsis-associated acute kidney injury without the research infrastructure previously required by the registry, significantly expanding patient access.
- Counterparty
- FDA